Status:
RECRUITING
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
Lead Sponsor:
Ace Cells Lab Limited
Conditions:
Hypertensive Nephropathy
Auto Immune Disorders
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologie...
Detailed Description
Study Objectives Primary Objective: To evaluate the effect of ACE Reno on urinary albumin-to-creatinine ratio (ACR) after 12 weeks of treatment in patients with nephropathy of diverse etiologies. S...
Eligibility Criteria
Inclusion
- Adults (≥18 years) with nephropathy of any degree (microalbuminuria, overt proteinuria, CKD stages 1-5 not on dialysis, or post-transplant with proteinuria). Stable background therapy with ACEi/ARB, SGLT2i, or MRA allowed.
Exclusion
- Recent kidney transplant (\<12 months). Uncontrolled acute infection or unstable autoimmune disease. Pregnancy or lactation. Known hypersensitivity to study components.
Key Trial Info
Start Date :
September 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07187713
Start Date
September 20 2025
End Date
December 31 2026
Last Update
September 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
British Centre For Regenerative medicine BCRMED Global
Giza, GZ, Egypt, 12311